Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM
Philippe Moreau(Centre National de la Recherche Scientifique), Simon J. Harrison(Peter MacCallum Cancer Centre), Thierry Façon(Université de Lille), Shaji Kumar(Mayo Clinic), Sari H. Enschede(AbbVie (United States)), Andrew W. Roberts(The Royal Melbourne Hospital), Ahmed Hamed Salem(Ain Shams University), Jeremy A. Ross(AbbVie (United States)), Kevin J. Freise(AbbVie (United States)), Cyrille Touzeau(Centre National de la Recherche Scientifique), Wijith Munasinghe(AbbVie (United States)), Joel D. Leverson(AbbVie (United States)), Paulo Maciag(AbbVie (United States)), Jia Jia(Hubei University of Medicine), Amit B. Agarwal(University of Arizona), Jaclyn Cordero(AbbVie (United States)), Elizabeth A. Punnoose(University Hospital Cologne), Maria Verdugo(AbbVie (United States)), Asher Chanan‐Khan(WinnMed)
Cited by 271
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k